HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Evaxion Biotech (NASDAQ:EVAX) and maintained a price target of $14.
August 16, 2024 | 9:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Evaxion Biotech and maintained a price target of $14.
The reiteration of a Buy rating and maintenance of a $14 price target by HC Wainwright & Co. is likely to positively impact Evaxion Biotech's stock price in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100